An open-label trial of escitalopram in children and adolescents with social anxiety disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 6, 2007, Pages 751-759

  Isolan, Luciano ^a,b   Pheula, Gabriel ^a,b   Salum Jr , Giovanni Abrahão ^a,b   Oswald, Sylvia ^a,b   Rohde, Luis Augusto ^a,b   Manfro, Gisele Gus ^a,b,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ANXIETY DISORDER; APPETITE; ARTICLE; AUTOMUTILATION; BLOOD PRESSURE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; EVENING DOSAGE; FEMALE; FLU LIKE SYNDROME; HUMAN; INSOMNIA; MALE; MORNING DOSAGE; NAUSEA; NERVOUSNESS; OPEN STUDY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PULSE RATE; QUALITY OF LIFE; RATING SCALE; SCHOOL CHILD; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOCIAL PHOBIA; SOMNOLENCE; SUICIDAL IDEATION; TREATMENT RESPONSE; TREMOR;

ADOLESCENT; CITALOPRAM; FEMALE; HUMANS; MALE; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 38549133434     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2007.0007     Document Type: Article

References (35)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4 th edition. Washington (DC), American Psychiatric Press, 1994.
2. Beidel DC, Turner SM, Morris TL: A new inventory to assess social anxiety and phobia: The Social Phobia and Anxiety Inventory for Children. Psychol Assess 7:73-79, 1995.
3. Bilyc-Fleitlich B, Goodman R: Prevalence of child and adolescent psychiatric disorders in southeast Brazil. J Am Acad Child Adolesc Psychiatry 43:727-734, 2004.
4. Birmaher B, Waterman S, Ryan N, Cully M, Balach L, Ingram J, Brodsky M: Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 33:993-999, 1994.
5. Birmaher B, Khetarpal S, Brent DA, Cully M, Balach L, Kaufman J, Neer SM: The Screen for Child and Anxiety Related Emotional Disorders (SCARED): Scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry 36:545-553, 1997.
6. Birmaher B, Brent DA, Chiappetta L, Bridge J, Monga S, Baugher M: Psychometric properties of the Screen for Child and Anxiety Related Emotional Disorders (SCARED): A replication study. J Am Acad Child Adolesc Psychiatry 38:1230-1236, 1999.
7. Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, Bridge J, Heo J, Brent DA: Fluoxetine for the treatment of childhood anxiety disorders. J Am Child Adolesc Psychiatry 42:415-423, 2003.
8. Burke WJ, Gergel I, Bose A: Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63:331-336, 2002.
9. Compton SC, Grant PJ, Chrisman AK, Gammon PJ, Brown VL, March JS: Sertraline in children and adolescents with social anxiety disorder: An open trial. J Am Child Adolesc Psychiatry 40:564-571, 2001.
10. Chavira DA, Stein MB: Combined psychoeducation and treatment with selective serotonin reuptake inhibitors for youth with generalized social anxiety disorder. J Child Adolesc Psychopharmacol 12:47-54, 2002.
11. Davidson JR, Bose A, Korotzer A, Zheng H: Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose study. Depress Anxiety 19:234-240, 2004.
12. Edwards TC, Huebner CE, Connell FA, Patrick DL: Adolescent quality of life, Part I: Conceptual and measurement model. Journal of Adolesc 25:275-286, 2002.
13. Fairbanks JM, Pine DS, Tancer NK, Dummit ES III, Kentgen LM, Martin J, Asche BK, Klein RG: Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. J Child Adolesc Psychopharmacol 7:17-29, 1997.
14. Gauer GJ, Picon P, Vasconcellos SJ, Turner SM, Beidel DC: Validation of the Social Phobia and Anxiety Inventory for Children (SPAI-C) in a sample of Brazilian children. Braz J Med Biol Res 38:795-800, 2005.
15. Guy W: ECDUE Assessment Manual for Psychopharmacology, rev. ed. Rockville (Maryland), National Institute of Mental Health, 1976.
16. Hyttel J, Bogeso KP, Perregaard J, Sanches C: The pharmacological effect of citalopram resides in the (S) - (+)-enantiomer. J Neural Transm Gen Sect 88:157-160, 1992.
17. Isolan LR, Zeni CP, Mezzommo K, Blaya C, Kipper L, Heldt E, Manfro GG. Behavioral inhibition and history of childhood anxiety disorders in Brazilian adult patients with panic disorder and social anxiety disorder. Rev Bras Psychiatr 27:97-100, 2005.
18. Kasper S, Stein DJ, Loft H, Nil R: Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186:222-226, 2005.
19. Kessler RC: The impairments caused by social phobia in the general population: Implications for intervention. Acta Psychiatr Scand 108:19-27, 2003.
20. Mancini C, Van Ameringen M, Bennett M, Paterson B, Watson C: Emerging treatments for child and adolescent social phobia: A review. J Child Adolesc Psychopharmacol 15:589-607, 2005.
21. Matza LS, Swensen AR, Flood EM, Secnik K, Leidy NK: Assessment of health-related quality of life in children: A review of conceptual, methodological, and regulatory issues. Value Health 7:79-92, 2004.
22. Orvashel H: Psychiatric interviews suitable for use in research with children and adolescents. Psychopharmacol Bull 21:737-745, 1985.
23. Otto MW, Pollack MH, Maki KM, Gould RA, Worthington JJ 3rd, Smoller JW, Rosenbaum JF. Childhood history of anxiety disorders among adults with social anxiety disorder: Rates, correlates, and comparisons with panic disorder. Depress Anxiety 14:209-213, 2001.
24. Owley T, Walton L, Salt J, Gutter SJ Jr, Winnega M, Leventhal BL, Cook EH Jr: An open-label trial of escitalopram in pervasive developmental disorders. J Am Child Adolesc Psychiatry 44:343-348, 2005.
25. Patrick DL, Edwars TC, Topolski TD: Adolescent quality of life, Part II: Initial validation of a new instrument. J Adolesc 25:287-300, 2002.
26. Pine DS, Cohen P, Gurley D, Brook J, Ma Y: The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry 55:56-64, 1998.
27. RUPP Anxiety Study Group: Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 344:1279-1285, 2001.
28. Seidel L, Walkup JT: Selective serotonin reuptake inhibitor use in the treatment of the pediatric non-obsessive-compulsive disorder anxiety disorders. J Child Adolesc Psychopharmacol 16:171-179, 2006.
29. Simon G: The antidepressant quandary - considering suicide risk when treating adolescent depression. N Engl J Med 28:2722-2723, 2006.
30. Stahl SM, Gergel I, Li D: Escitalopram in the treatment of panic disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64:1322-1327, 2003.
31. Stein MB, Fuetsch M, Muller N, Hofler M Lieb R, Wittchen HU: Social anxiety disorder and the risk of depression: A prospective community study of adolescents and young adults. Arch Gen Psychiatry 58:251-256, 2001.
32. Wade A, Michael Lemming O, Bang Hedegaard K: Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17:95-102, 2002.
33. Wagner KD, Berard R, Stein MB, Wethehold E, Carpenter DJ, Perera P, Gee M, Davy K, Machin A: A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61:1153-1162, 2004.
34. Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K: A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 45:280-288, 2006.
35. Wittchen HU, Nelson GB, Lachner G: Prevalence of mental disorders and psychosocial impairments in adolescents and young adults. Psychol Med 28:109-126, 1998.